- Home
- ZTEK vs IMUX Comparison
ZTEK vs IMUX Comparison
Compare ZTEK & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- IMUX
- Stock Information
- Founded
- ZTEK 2008
- IMUX 2016
- Country
- ZTEK Canada
- IMUX United States
- Employees
- ZTEK N/A
- IMUX N/A
- Industry
- ZTEK Major Chemicals
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- ZTEK Industrials
- IMUX Health Care
- Exchange
- ZTEK Nasdaq
- IMUX Nasdaq
- Market Cap
- ZTEK 89.3M
- IMUX 92.2M
- IPO Year
- ZTEK N/A
- IMUX N/A
- Fundamental
- Price
- ZTEK $0.76
- IMUX $0.68
- Analyst Decision
- ZTEK
- IMUX Strong Buy
- Analyst Count
- ZTEK 0
- IMUX 5
- Target Price
- ZTEK N/A
- IMUX $6.00
- AVG Volume (30 Days)
- ZTEK 58.9K
- IMUX 1.3M
- Earning Date
- ZTEK 11-14-2025
- IMUX 11-13-2025
- Dividend Yield
- ZTEK N/A
- IMUX N/A
- EPS Growth
- ZTEK N/A
- IMUX N/A
- EPS
- ZTEK N/A
- IMUX N/A
- Revenue
- ZTEK $657,134.00
- IMUX N/A
- Revenue This Year
- ZTEK N/A
- IMUX N/A
- Revenue Next Year
- ZTEK N/A
- IMUX N/A
- P/E Ratio
- ZTEK N/A
- IMUX N/A
- Revenue Growth
- ZTEK 2225.73
- IMUX N/A
- 52 Week Low
- ZTEK $0.62
- IMUX $0.56
- 52 Week High
- ZTEK $1.84
- IMUX $1.42
- Technical
- Relative Strength Index (RSI)
- ZTEK 46.41
- IMUX 41.13
- Support Level
- ZTEK $0.75
- IMUX $0.67
- Resistance Level
- ZTEK $0.83
- IMUX $0.78
- Average True Range (ATR)
- ZTEK 0.06
- IMUX 0.06
- MACD
- ZTEK -0.01
- IMUX -0.00
- Stochastic Oscillator
- ZTEK 22.48
- IMUX 16.44
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.